JPO

Alnylam Pharmaceuticals this week announced that the Japanese Patent Office has upheld certain key claims within the company's Tuschl-II patent during invalidation proceedings initiated at the request of Bio Think-Tank, a Japanese company.

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

The patent claims siRNAs containing proprietary 2’-O-methyl structures.

The patent covers a proprietary nucleic acid condensing and delivery peptide motif, as well as its use with therapeutic nucleic acids.

According to Alnylam, the patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs."

The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.